Multipotent mesenchymal stem cells (MSCs) are a heterogeneous population of cells which reside in a variety of tissues. They differentiate into several mesodermal lineages, secrete a multitude of trophic factors and contribute to tissue homeostasis. MSCs are able to exert immunosuppressive activities by interfering with inflammatory cytokine production and with T- and B-cell proliferation. These immunomodulating properties make MSCs promising candidates for the treatment of chronic inflammatory and autoimmune disorders. There are, however, certain caveats involved including inappropriate migration of cells in the body, immune rejection, tumor formation, or graft versus host disease (GvHD).
This book investigates the current state of the MSC-dependent therapy of chronic inflammatory disorders and autoimmune diseases. Among the covered topics are GvHD, chronic kidney, liver and lung disease, ischemic heart and inflammatory bowel disease, diabetes, osteoarthritis, various rheumatic and neurological disorders and, lastly, tumors and solid organ transplantations. This book also questions the immunoprivileged status of MSCs, discusses the therapeutic role of MSCs in experimental animal disease models and their translation to the corresponding human disorders, envisions a role for MSCs in tumor interventions and, lastly, describes a systems biology approach for stem cells and inflammation.
Inhaltsverzeichnis
1;Preface;5 2;Contributing authors;7 3;1 Mesenchymal stem cells in the context of stem cell biology;19 3.1;1.1 Introduction Definitions;19 3.2;1.2 Embryonic and adult tissue stem cells;20 3.3;1.3 Adult tissue stem cells and progenitors;21 3.4;1.4 Adult stem cells and tissue homeostasis;23 3.5;1.5 Adult stem cell niches;23 3.6;1.6 Commitment and differentiation;25 3.7;1.7 The case for bone marrow MSCs;26 3.8;1.8 Clinical prospects;28 3.9;1.9 Concluding remark;29 3.10;References;29 4;2 Are mesenchymal stem cells immune privileged?;35 4.1;2.1 Introduction Definition of mesenchymal stem cells (MSCs);35 4.2;2.2 The immunosuppressive effect of MSCs on immune cells;36 4.3;2.3 The potential clinical benefits of MSCs as immunosuppressants;38 4.4;2.4 The mechanisms of immunosuppression by MSCs;39 4.5;2.5 The mechanisms of immunosuppression by human MSCs;39 4.6;2.6 Immunosuppression by murine MSCs and the species difference underlying the mechanisms of immunosuppression by MSCs;43 4.7;2.7 Immunosuppression mediated by fibroblasts;46 4.8;2.8 The mechanisms of the immunosuppressive effect of MSCs are shared with other nonstromal cells;46 4.9;2.9 How long can MSCs survive in vivo?;46 4.10;2.10 Conclusion and discussion;47 4.11;References;49 5;3 Mesenchymal stem cell therapies for autoimmune diseases;55 5.1;3.1 Introduction;55 5.2;3.2 Autoimmune disease;57 5.3;3.3 Mesenchymal stem cells (MSCs);59 5.3.1;3.3.1 Animal models;60 5.4;3.4 Results of MSCs clinical trials;62 5.5;3.5 Safety of MSCs;63 5.6;3.6 Conclusion;63 5.7;References;64 6;4 Mesenchymal stem cells in osteoarthritis and rheumatic disease;69 6.1;4.1 Introduction Rheumatic diseases;69 6.2;4.2 Rheumatoid arthritis (RA);69 6.3;4.3 Osteoarthritis (OA);71 6.4;4.4 MSCs in healthy and rheumatic joint tissues;73 6.5;4.5 Application of MSCs in rheumatic diseases;74 6.6;4.6 MSCs application in animals;78 6.7;4.7 Clinical studies in humans;84 6.8;4.8 Risks and benefits of MSCs treatments in rheumatic diseases;86 6.9;References;88 7;
5 Mesenchymal stem cells in enthesis formation and repair;101 7.1;5.1 Introduction;101 7.2;5.2 Structure of the tendon-to-bone junction;102 7.3;5.3 Enthesis resident T cells are involved in enthesopathies provoking inflammation and bone remodeling;103 7.4;5.4 Biomaterials and growth factor-dependent regeneration of tendon-to-bone junctions;105 7.5;5.5 Biomechanical stimulation for enthesis repair;106 7.6;5.6 Mesenchymal stem cells (MSCs);106 7.7;5.7 Stem cell-dependent approaches for repair of osteotendinous junctions;107 7.8;5.8 Stem cell-dependent delivery of growth factors;109 7.9;5.9 Stem cell-dependent delivery of tenogenic transcription factors;111 7.10;5.10 Stem cell-dependent delivery of matrix metalloproteinases;112 7.11;5.11 Trophic activities of MSCs in enthesis repair;112 7.12;5.12 Outlook;113 7.13;Acknowledgment;114 7.14;References;114 8;6 Mesenchymal stem cells for clinical/therapeutic interventions of graft-versus-host disease;119 8.1;6.1 Clinical graft-versus-host disease;119 8.2;6.2 Chronic graft-versus-host disease;120 8.3;6.3 Rationale to use mesenchymal stromal cells for treatment of GvHD;121 8.4;6.4 Experience of MSCs in clinical acute graft-versus-host disease;123 8.5;6.5 Treatment of acute GvHD with stromal cells from alternate sources, adipose tissue-derived, umbilical cord blood-derived or fetal membrane-derived stromal cells;128 8.6;6.6 Mesenchymal stromal cells for treatment of chronic graft-versus-host disease;129 8.7;6.7 Clinical trials of prophylaxis with mesenchymal stromal cells for graft-versus-host disease;131 8.8;6.8 Discussion on clinical use of mesenchymal stem cells;133 8.9;6.9 How should we best utilize MSC treatment of GvHD?;134 8.10;References;137 9;7 Mesenchymal stem cells for graft-versus-host disease in experimental animal models;143 9.1;7.1 Introduction Experimental models of graft-versus-host disease (GvHD);143 9.2;7.2 Immunobiology of experimental GvHD;145 9.3;7.3 Mesenchymal stromal cells in mice;146 9.4;7.4 Mesenchyma
l stromal cells and mouse models of graft-versus-host disease;148 9.5;References;154 10;8 Mesenchymal stem cells and organ transplantation: initial clinical results;161 10.1;8.1 Introduction;161 10.2;8.2 Rationale for the use of MSCs in organ transplantation;162 10.2.1;8.2.1 Shortage of donor organs for transplantation;162 10.2.2;8.2.2 Ischemia-reperfusion injury;163 10.2.3;8.2.3 Chronic immunosuppression;163 10.3;8.3 Considerations regarding the choice of the clinical protocols;164 10.3.1;8.3.1 Definition, identity and product release criteria for human MSCs preparations;165 10.3.2;8.3.2 Source of human MSCs;165 10.3.3;8.3.3 Potential interactions between MSCs and concomitant therapy;167 10.3.4;8.3.4 Safety of MSCs-based treatments;168 10.4;8.4 Clinical MSCs and solid organ transplantation trials;169 10.4.1;8.4.1 Autologous MSCs in the induction phase with standard immunosuppression;169 10.4.2;8.4.2 Autologous MSCs in the induction phase with avoidance of biologics at induction and reduced maintenance immunosuppression;172 10.4.3;8.4.3 Allogeneic MSCs in the induction phase;173 10.4.4;8.4.4 Autologous MSCs for the treatment of biopsy-proven subclinical rejection, progressive renal interstitial fibrosis and tubular atrophy;174 10.5;8.5 Future perspectives;176 10.6;Acknowledgments:;176 10.7;References;177 11;9 Stem cell therapy in patients with ischemic heart disease;181 11.1;9.1 Introduction;181 11.2;9.2 Cell type and source for clinical therapy;183 11.3;9.3 Mechanisms behind regeneration of damaged myocardium;184 11.4;9.4 Preclinical experience with stem cells for IHD;187 11.5;9.5 Cell-based therapy in patients with IHD;187 11.6;9.6 MSCs in patients with IHD;189 11.7;9.7 Ongoing clinical trials using MSCs;192 11.8;9.8 Cell delivery and engraftment;192 11.9;9.9 Perspectives;196 11.10;9.10 Conclusion;197 11.11;References;197 12;10 Mesenchymal stem cells as a strategy for the treatment of multiple sclerosis and other diseases of the central nervous system;203 12.1;10.
1 Introduction;203 12.2;10.2 MSCs transplantation for neurological diseases: why, which, and how;204 12.3;10.3 Vascular diseases: ischemic stroke;205 12.3.1;10.3.1 Preclinical studies;205 12.3.2;10.3.2 Clinical studies;207 12.4;10.4 Trauma spinal cord injury;208 12.4.1;10.4.1 Preclinical studies;209 12.4.2;10.4.2 Clinical studies;210 12.5;10.5 Extrapyramidal diseases;210 12.5.1;10.5.1 Parkinsons disease (PD);210 12.5.2;10.5.2 Preclinical studies;211 12.5.3;10.5.3 Clinical studies;212 12.5.4;10.5.4 Huntingtons disease (HD);212 12.5.5;10.5.5 Preclinical studies;213 12.6;10.6 Multiple system atrophy (MSA);214 12.6.1;10.6.1 Preclinical studies;214 12.6.2;10.6.2 Clinical studies;215 12.7;10.7 CNS demyelinating diseases: multiple sclerosis;215 12.7.1;10.7.1 Preclinical studies;216 12.7.2;10.7.2 Clinical studies;217 12.8;10.8 Motor neuron diseases: amyotrophic lateral sclerosis (ALS);218 12.8.1;10.8.1 Preclinical studies;218 12.8.2;10.8.2 Clinical studies;219 12.9;10.9 Dementia: Alzheimers disease (AD);220 12.9.1;10.9.1 Preclinical studies;220 12.9.2;10.9.2 Clinical studies;221 12.10;10.10 Concluding remarks;221 12.11;References;222 13;11 Mesenchymal stem cells for the treatment of inflammatory bowel disease;229 13.1;11.1 Introduction;229 13.2;11.2 Immunology and intestinal barrier function;230 13.3;11.3 Cell-based treatments for IBD;233 13.3.1;11.3.1 Hematopoietic cell transplantation;233 13.4;11.4 T regulatory cells (Tregs);234 13.5;11.5 Mesenchymal stem cells (MSCs);235 13.5.1;11.5.1 Immunologic basis for MSCs and IBD;235 13.6;11.6 MSC homing and engraftment;237 13.7;11.7 MSC clinical trials;240 13.8;11.8 Summary and future directions;242 13.9;References;244 14;12 Mesenchymal stem cells in chronic lung diseases: COPD and lung fibrosis;251 14.1;12.1 Introduction;251 14.2;12.2 Idiopathic pulmonary fibrosis;253 14.3;12.3 MSCs and animal models of fibrotic lung disorders;256 14.4;12.4 Chronic obstructive pulmonary disease (COPD);264 14.5;12.5 Conclusions and future directio
ns;270 14.6;Acknowledgments;271 14.7;References;271 15;13 Mesenchymal stem cells as therapeutics for liver repair and regeneration;281 15.1;13.1 Introduction;281 15.2;13.2 Cell therapy for liver disease;282 15.3;13.3 The ideal cell for liver regeneration;283 15.4;13.4 Mesenchymal stem cells (MSCs) as cellular therapeutics;284 15.5;13.5 MSCs for treating liver disease;287 15.5.1;13.5.1 In vitro models to study MSCs hepatic differentiation;287 15.5.2;13.5.2 In vivo models to study MSCs as cellular therapies for liver disease/injury;288 15.6;13.6 The fetal sheep model;291 15.7;13.7 Clinical trials using MSCs for liver regeneration;297 15.8;13.8 Summary/Conclusions:;298 15.9;References;299 16;14 Mesenchymal stem cells attenuate renal fibrosis;311 16.1;14.1 Introduction Kidney function;311 16.2;14.2 Kidney dysfunction and chronic kidney disease (CDK);313 16.2.1;14.2.1 Molecular and cellular interaction in renal fibrosis;314 16.3;14.3 Mesenchymal stem cells (MSCs): Definition and basic features;316 16.3.1;14.3.1 Therapeutic potential of MSCs and their mechanisms of action in the repair/regeneration of tissue injury;316 16.4;14.4 MSCs and kidney diseases;319 16.4.1;14.4.1 MSCs have a prominent antifibrotic effect in distinct models of experimental chronic kidney diseases;319 16.4.2;14.4.2 Mechanisms related to MSCs prevent renal fibrosis;321 16.5;14.5 Final considerations;322 16.6;References;323 17;15 Immunomodulation by mesenchymal stem cells a potential therapeutic strategy for type 1 diabetes;327 17.1;15.1 Introduction;327 17.2;15.2 Mechanisms of immunomodulation;328 17.3;15.3 MSC therapy for type 1 diabetes (T1D);329 17.3.1;15.3.1 Why does MSC therapy hold value in T1D?;329 17.3.2;15.3.2 Preclinical studies to prevent and reverse T1D;330 17.3.3;15.3.3 MSC implications in islet cell transplantation;331 17.3.4;15.3.4 MSCs and clinical trials for T1D;332 17.4;15.4 Safety of MSC therapy;333 17.5;References:;333 18;16 Fibrogenic potential of human multipotent mesenchymal st
em cells in inflammatory environments;337 18.1;16.1 Introduction;337 18.2;16.2 Fibrogenic potential in ex vivo expanded MSCs;338 18.3;16.3 Evidence of MSCs infiltration into tumor stroma;339 18.4;16.4 Controversies regarding therapeutic benefits of bone marrow-derived MSCs in liver fibrosis;340 18.5;16.5 Limited contribution of MSCs to liver regeneration in acute liver injury;342 18.6;16.6 Conclusion;344 18.7;References;344 19;17 Mesenchymal stem cells and the tumor microenvironment;349 19.1;17.1 Introduction;349 19.2;17.2 The tumor microenvironment and its role in cancer initiation and progression;351 19.3;17.3 How do we define MSCs in cancer?;352 19.4;17.4 What are the roles of MSCs in cancer progression?;353 19.4.1;17.4.1 Effect of MSCs on tumor cell proliferation;355 19.4.2;17.4.2 MSCs promote survival;355 19.4.3;17.4.3 MSCs are proangiogenic;356 19.4.4;17.4.4 MSCs have an immunosuppressive function;356 19.4.5;17.4.5 MSCs promote epithelial to mesenchymal transition;357 19.5;17.5 How do tumor cells communicate with MSCs?;359 19.6;17.6 Are MSCs recruited by tumor cells?;361 19.7;17.7 Can we target MSCs in human cancer?;363 19.8;17.8 Conclusion;364 19.9;References;364 20;18 Mesenchymal stem cells as a carrier for tumor-targeting therapeutics;371 20.1;18.1 Introduction;371 20.2;18.2 Enhanced angiogenesis as a target for tumor therapy;372 20.3;18.3 Why current therapies are not effective enough;373 20.3.1;18.3.1 Shortcomings of current anti-angiogenic pharmaceuticals;374 20.4;18.4 Why mesenchymal stem cells would be useful for tumor targeting;376 20.4.1;18.4.1 The tumor-homing properties of MSCs;376 20.4.2;18.4.2 MSCs as a diagnostic tool;379 20.4.3;18.4.3 Antitumor effects of unmanipulated MSCs;379 20.4.4;18.4.4 Vesicular communication of MSCs: How MSCs can be used as a drug-delivery vehicle;380 20.5;18.5 MSCs as a gene product-delivering vehicle;382 20.5.1;18.5.1 Genetically modified MSCs for therapeutic delivery;382 20.5.2;18.5.2 Potential for MSCs-delivered anti
-angiogenic therapies;383 20.5.3;18.5.3 MSCs-mediated tumor-homing of oncolytic adenovirus enhances tumor therapy;384 20.5.4;18.5.4 Delivery of TRAIL by genetically modified MSCs to induce apoptosis;385 20.5.5;18.5.5 Tumor-specific promoter-driving thymidine kinase (TK) expression for prodrug conversion;385 20.6;18.6 Methods of therapeutic MSCs administration;387 20.7;18.7 The advantage of MSCs being immunoprivileged;388 20.8;18.8 Sources of acquiring MSCs for tumor therapy;389 20.9;18.9 Remaining challenges for the use of MSCs to deliver therapeutics;390 20.9.1;18.9.1 The immunoprivileged nature of MSCs;390 20.9.2;18.9.2 Varying responses to MSCs depending on cancer type, injection site, etc.;390 20.9.3;18.9.3 Changes in MSCs induced by cancer cells within the tumor microenvironment;391 20.10;18.10 Summary and prospective;393 20.11;Acknowledgments;393 20.12;References;394 21;19 Systems biology approach to stem cells, tissues and inflammation;399 21.1;19.1 Introduction;399 21.2;19.2 Biological aspects;400 21.2.1;19.2.1 Cells are the regulatory units;400 21.2.2;19.2.2 Influence of cell number and phenotype;401 21.3;19.3 Technological aspects;401 21.3.1;19.3.1 Technology and type of molecules;401 21.3.2;19.3.2 When pictures start moving;402 21.4;19.4 Mathematical aspects;403 21.4.1;19.4.1 Comparative statistics and interpretation;403 21.4.2;19.4.2 Interpretation based on pre-existing knowledge;404 21.4.3;19.4.3 Network models;404 21.5;19.5 Systems biology of differentiation;406 21.6;19.6 Important tasks;407 21.7;19.7 Conclusion;408 21.8;References;409 22;Index;413